key: cord-0286127-mfhug37f
authors: Nikitin, Pavel A.; DiMuzio, Jillian M.; Dowling, John P.; Patel, Nirja B.; Bingaman-Steele, Jamie L.; Heimbach, Baron C.; Henriquez, Noeleya; Nicolescu, Chris; Polley, Antonio; Sikorski, Eden L.; Howanski, Raymond J.; Nath, Mitchell; Shukla, Halley; Scheaffer, Suzanne M.; Finn, James P.; Liang, Li-Fang; Smith, Todd; Storm, Nadia; McKay, Lindsay G. A.; Johnson, Rebecca I.; Malsick, Lauren E.; Honko, Anna N.; Griffiths, Anthony; Diamond, Michael S.; Sarma, Purnanand; Geising, Dennis H.; Morin, Michael J.; Robinson, Matthew K.
title: Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
date: 2022-05-18
journal: bioRxiv
DOI: 10.1101/2021.10.18.464900
sha: 0db9548dc720ba1a844832cd5da829d5263b1996
doc_id: 286127
cord_uid: mfhug37f

Using an unbiased interrogation of the memory B cell repertoire of convalescent COVID-19 patients, we identified human antibodies that demonstrated robust antiviral activity in vitro and efficacy in vivo against all tested SARS-CoV-2 variants. Here, we describe the pre-clinical characterization of an antibody cocktail, IMM-BCP-01, that consists of three unique, patient-derived recombinant neutralizing antibodies directed at non-overlapping surfaces on the SARS-CoV-2 spike protein. Two antibodies, IMM20184 and IMM20190 directly block spike binding to the ACE2 receptor. Binding of the third antibody, IMM20253, to its unique epitope on the outer surface of RBD, alters the conformation of the spike trimer, promoting release of spike monomers. These antibodies decreased SARS-CoV-2 infection in the lungs of Syrian golden hamsters, and efficacy in vivo efficacy was associated with broad antiviral neutralizing activity against multiple SARS-CoV-2 variants and robust antiviral effector function response, including phagocytosis, ADCC, and complement pathway activation. Our pre-clinical data demonstrate that the three antibody cocktail IMM-BCP-01 shows promising potential for preventing or treating SARS-CoV-2 infection in susceptible individuals. One sentence summary IMM-BCP-01 cocktail triggers Spike Trimer dissociation, neutralizes all tested variants in vitro, activates a robust effector response and dose-dependently inhibits virus in vivo.

With over 472 million cases and more than 6.1 million deaths worldwide (Johns Hopkins 45 University Coronavirus Resource Center), the SARS-CoV-2 pandemic continues to pose 46 extraordinary health and economic challenges. The scientific community has mitigated this threat 47 through the discovery and launch of a myriad of vaccines and therapeutics to prevent or treat 48 infections. While the initial data for the spike (S) protein-directed vaccines have been impressive, 49 the current rate of protection against variants of concern is decreasing, which was predicted to 50 occur due to viral escape and patient immunodeficiency or immunosuppression (1) (2) (3) (4) (5) (6) . 51 52 As such, the discovery and development of effective antibody therapies for passive immunization 53 with broad range of reactivity is likely to be an important alternative approach to vaccination. The 54 use of convalescent plasma against SARS-CoV-2 initially yielded mixed results (7, 8), however a 55 recent retrospective cohort study showed reduced mortality in treated patients (9) outlining the 56 need for a more robust and more standardized antiviral antibody cocktail. A phase 3 clinical trial 57 with Lilly's Bamlanivimab was halted on the basis of data showing no improvement in clinical 58

outcomes. An early Regeneron trial with a 2-antibody mixture was also paused based on a potential 59 safety signal and an unfavorable risk/benefit profile (10). Nonetheless, subsequent data 60 demonstrated that S-protein-directed antibodies can have significant efficacy and safety, and both 61 the Lilly and Regeneron antibody cocktail candidates received Emergency Use Authorization 62 (EUA) from the US FDA in November 2020, although the EUA for Bamlanivimab was later 63 withdrawn and distribution of the Bamlanivimab/Etesevimab cocktail is now limited to areas 64

where resistant variant frequency is below 5%. Another S-protein specific antibody, Sotrovimab, 65 administered to animals 6 hours after viral challenge (treatment paradigm), we observed that 178 IMM20190 or 2-Ab combinations of IMM20184/IMM20190 or IMM20190/IMM20253 led to 179 robust viral clearance (Fig 2B) . However, the greatest clearance was observed with the 3-Ab 180 cocktail. Five of the six animals in this cohort showed an approximately 2.5-log10 reduction of 181 viral titer in the lung on day 4 post viral challenge. In a follow-up study, the 3-Ab cocktail 182 decreased the viral titer in the lungs of animals inoculated with a high-titer (3.3 x 10 5 TCID50) of 183 WA_CDC-WA1/2020 (REF variant) by over 100-fold. This efficacy was observed when the 184 antibodies were administered at either 1:1:1 (p=0.0077) or 1:0.5:0.5 185 (IMM20190:IMM20184:IMM20253; p=0.0143) molar ratios (Fig 2C) . However, when subjected 186

to an F-test, the variability in clearance level in 1:0.5:0.5 group was higher (P < 0.0001) than when 187 animals were treated with an equimolar ratio cocktail (Fig 2C) . These studies were performed 188 using a viral inoculum that was approximately 10-fold higher than what is typically used to 189 evaluate efficacy of antibody therapies (23, 25) . When repeated at a lower inoculating dose (3.3 x 190 10 4 TCID50 per animal) (Fig 2D) When administered via i.p. injection, the IMM-BCP-01 cocktail generally followed first-order 215 absorption and elimination process with a half-life of approximately 100 hours in hamsters 216 ( Supplemental Fig 2A, B) . Unexpectedly, we observed that some animals treated with IMM-217 BCP-01 had lung titers equivalent to non-treated controls. To better understand that lack of effect, 218 terminal bleeds were assessed for levels of human IgG in the plasma. Those studies demonstrated 219 that variability in viral clearance correlated directly with systemic distribution of IMM-BCP-01 220 (Supplemental Fig 2C) . Animals that exhibited lower viral lung titers were associated with 221 terminal plasma levels of IMM-BCP-01 greater than 3-5 µg/mL. In contrast, IMM-BCP-01 was 222 not observed at appreciable levels in the blood of animals that failed to clear virus from the lungs, 223

To better understand the 3-Ab cocktail, we performed a series of experiments focusing on the 246 combinatorial contributions of the component antibodies to the overall neutralizing activity. We 247 tested 2-Ab mixtures of IMM20190 (1x concentration) with either IMM20184 (1x) or IMM20253 248 (1x), and a 3-Ab combination of IMM20190 (1x) with IMM20184/IMM202053 (0.5x each) in 249 pseudovirus neutralization assays (Supp. Fig 3) . Double and triple antibody combinations dose-250 dependently neutralized pseudovirus variants corresponding to three VOC (Supp. Fig 3A, B) . We 251 calculated each antibody contribution to the observed neutralizing effect using SynergyFinder 2.0 252 (26)A score below -10 suggests an antagonistic (competitive) effect; a score between -10 and 10 253 reflects an additive effect; and a score above 10 suggests a synergistic effect of the combined 254 treatment. We detected a concentration-dependent synergistic potential of combinations (Supp. 255 Fig 3C) . In variants that IMM20190 potently neutralized, such as WA1/2020 and Epsilon, 256 antibody combinations are mainly additive, as IMM20190 neutralization was sufficient and did 257 not require the two other antibodies. In variants where the potency of IMM20190 was reduced, 258 such as Beta and Gamma, combinations were also additive. In addition, IMM20184 and 259 IMM20253 antibodies as a double combination had an additive neutralizing effect against these 260 variants (Supp. Fig 3D) . We observed the highest synergistic potential of the 3-Ab combination 261 IMM20190/184/253 for the Alpha variant, where each of the single antibodies neutralized with 262 comparable IC50's ( Fig 2D) . In this variant background, the triple antibody combination 263 outperformed all three of the individual antibodies. Thus, the 3-Ab cocktail neutralized all tested 264 variants and was associated with additive or synergistic effects depending on the strain. Combined 265 with the observed antibody pharmacokinetics data (Supp . Fig 2A) , these data suggest that 266 administration of the 3-Ab cocktail (0.5 mg each) reaches serum concentrations in vast excess of 267 the IC50 neutralization concentrations observed for all SARS-CoV-2 variants tested, including the 268 Alpha, Beta, Gamma, and Delta (Supp. Fig 2, and Fig 2, 3) . 269 270 When extended to intact virus isolates, we observed equivalent, or better potency of the IMM-271 BCP-01 cocktail against WA1/2020, BavPat (D614G), Alpha, Beta, and Gamma variants 272 measured in focus (Fig 3E) or plaque (Fig 3F, G 3F, G; Supp. Fig 4) . Consistently with the data observed in vivo (Fig. 2H) Fig 4) . Although no 280 mutations present in the Omicron isolates mapped to critical binding residues for IMM20184 (Fig  281   1C) , the antibody lost neutralization potency. A partial loss of IMM20184 activity was observed 282 in plaque reduction assays with BA.1, but complete loss of neutralizing activity was observed 283 against BA.1.1 in the context of the FRNT assay (Fig 3G, Supp. Fig 4) . The IMM20184/253 284 combination showed an additive effect, compared to the IMM20253 antibody alone, in the plaque 285 assay ( Table 1 ) and (Fig. 3G) , that is in agreement with the result observed using Omicron isolate 286 in vivo (Fig. 2H) . 287 288 Finally, we observed a higher in vivo potency of IMM-BCP-01 cocktail, compared to its activity 289 by virus neutralization assays in vitro. We detected a 100-fold increase in EC50 of IMM-BCP-01 290 cocktail against Beta variant in both pseudovirus (Fig 3A) and authentic virus (Fig 3E) assays in 291 vitro that only resulted in a minor dose increase (from 0.3 mg to 0.5 mg per antibody) in vivo (Fig  292   2F , G and 3A), outlining the importance of in vivo studies for anti-SARS-COV-2 antibodies. We 293 performed in vitro neutralization assays at multiple facilities, including academic and industry 294 laboratories, and observed a ~10-fold difference in EC50s values for same virus variants (Alpha 295 variant as an example, Fig 3H) . retain intact IgG1 Fc domains and bind to the RBD in a non-competitive manner (Fig 1, Supp . 301 Fig 1H) . We hypothesized that IMM2019/184/253 might generate an oligoclonal response to S 302 protein that activates Fc-mediated effector functions including antibody-dependent cellular 303 cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and classical 304 complement pathway (CP) (Fig 4) . To test this hypothesis, we first measured antibody-induced 305 phagocytosis of Trimer-coated beads using a published method (30). All three human antibodies 306 induced phagocytosis of Trimer-coated beads in a dose-dependent manner relative to an IgG1 307 isotype control (Fig 4A) . Even a low (~15 pM) concentration of IMM20253 antibody potently 308 induced phagocytosis. The 3-Ab cocktail (IMM20190/184/253) demonstrated a higher phagocytic 309 score than a 2-Ab cocktail (IMM20184/253) or each individual antibody (Fig 3A) . We did not 310 observe phagocytosis of Trimer-coated beads in the presence of an IgG1 isotype control antibody. 311

Next, we evaluated activation of the classical CP by IMM20190/184/253 cocktail ( Figure 3B ). In 312 brief, we adapted a CP activation assay (31) and measured deposition of the complement 313 component C4 from serum of normal human donors on anti-S antibodies bound to Trimer-coated 314 surface. IMM20190 and IMM20253 antibodies bound to Trimer promoted detectable levels of C4 315 deposition. While IMM20184 binding to Trimer alone did not activate CP in this assay, the 2-Ab 316 cocktail IMM20184/253 induced C4 deposition on antibody-Trimer complexes (Fig 3B) . The 317 three antibody cocktail IMM20190/184/253 induced the most robust activation of C4 deposition. 318

Since all tested antibodies had the same intact heavy chain IgG1 Fc region, we hypothesized that 319 C4 deposition on Trimer-Ab immune complex might depend on the Fc epitope conformation and 320 accessibility as previously demonstrated for other antibodies (32, 33). Cryo-EM studies (Fig 1, The location of IMM20184 and IMM20190 epitopes suggests that these two antibodies likely 329 block ACE2 binding. To test this hypothesis, we performed a biochemical ELISA-based receptor 330 inhibition assay. The affinity of a soluble ACE2 protein to Wuhan-1, Alpha, and Beta variant 331

RBDs coated to an ELISA plate was evaluated in the presence of various concentrations of 332 antibodies of interest. Consistent with the data from the homogeneous time resolved fluorescence 333 (hTRF) assay (Supp. Table 1 ), IMM20184 potently inhibited ACE2 binding to all three RBD 334 variants (Fig 5A) . IMM20190 blocked ACE2 binding to Wuhan-1 and Alpha variant RBD 335 proteins, and partially decreased ACE2 binding to the Beta variant RBD. In contrast, IMM20253 336 did not fully block ACE2 interactions with any of the three RBD variants tested (Fig 5A) . A partial 337 inhibition of ACE2 binding by IMM20253 (up to 40%, depending on the concentration) was 338 detected for all three S variants tested. These data are consistent with the location of the IMM20253 339 epitope relative to the ACE2 binding site and suggest its neutralization occurs through a distinct 340 mechanism of action (see below). Finally, an equimolar mixture of IMM20190, IMM20185, and 341 IMM20253 antibodies disrupted ACE2 binding to all three tested RBD variants. The inhibitory 342 effect of a 3-Ab cocktail was more pronounced than the effect of each individual antibody. Of 343 note, we detected a minor ACE2 binding preference to Alpha RBD than to Beta RBD variant (Fig  344   6A , left panel). 345 346 IMM20190, IMM20184 and IMM20253 bind to soluble RBD and S1 proteins recapitulating 347

Steady-state binding of the three antibodies across a range of variants was characterized via hTRF 349 (Supp. Table 1 and Supp. Fig 6) . Each of the three antibodies was tested for binding against 350 isolated RBD or S1 protein encompassing over 20 different single and multiple mutations that 351 correspond to naturally occurring and predicted escape mutations. IMM20184 and IMM20253 352 retained picomolar EC50 binding to most of single and multiple point mutations tested, including 353 those present in VBM and VOC. Furthermore, IMM20253 exhibited some binding to SARS-CoV-354 1 Spike. In contrast, IMM20190 binding was reduced, to varying degrees, by K417N Antibody binding kinetics were measured using a multi-cycle kinetics protocol on a Biacore T200 361 surface plasmon resonance instrument. All three antibodies bound with high affinity to both RBD 362 and Trimer. (Fig 5B, C) . All three antibodies bound with rapid on-rates (ka > 2.95+E4 1/Ms) to 363

Trimer, but exhibited even faster on-rates (ka) to RBD. This effect was least pronounced for 364 IMM20190, suggesting that its epitope is the most accessible in the intact Trimer structure. 365 IMM20184 and IMM20253 bound to the RBD 17-and 19-fold faster than to the Trimer, 366

respectively. The dissociation of IMM20184 from Trimer (kd Trimer = 2.3E-04 1/s) was 6-fold slower 367 than from RBD (kd RBD =1.3E-03 1/s). This difference in dissociation suggests the antibody/Trimer 368 complex is stabilized through an avid binding mechanism between the antibody and two subunits 369 of the Trimer, consistent with the epitope mapping data (Fig 1) . IMM20253, despite exhibiting the 370 greatest difference (19-fold) in on-rates between the RBD and Trimer, has the fastest on-rate for 371 the Trimer of all three antibodies. This result suggests the epitope is readily accessible in the 372 context of the Trimer structure. 373 374 IMM20253 binding releases Spike monomers and facilitates protease cleavage. 375 IMM20253 disruption of Trimer into Spike monomers, detected by cryo-EM (Fig 1) , suggested 376 that the antibody might facilitate cleavage of S into S1 and S2. We used a previously published 377 method to evaluate Trimer sensitivity to protease cleavage in the presence of an antibody (34). 378

Briefly, Trimer protein was mixed with protease K in the presence of either (1) buffer only, (2) 379 human recombinant ACE2 protein, (3) IMM20253 or (4) IMM20190, an anti-S antibody that 380 recognizes ACE2-binding region, and incubated for 0, 15 and 60 minutes. Protease readily cleaved 381 S incubated with buffer after 60 min. ACE2 or IMM20190 appeared to partially decrease protease 382 cleavage at 60 min, perhaps due to steric hindrance. In contrast, IMM20253 induced S cleavage 383 after 15 min (Fig 5D) . In a complementary experiment, we evaluated S samples preincubated with 384 ACE2, IMM20253 or IMM202190 in the absence of protease. Samples were analyzed using a 385 standard "premix" protocol by dynamic light scattering (DLS). Incubation of S with ACE2 or 386 IMM20190 led to the generation of complexes and increased the size of particles, measured as an 387 increase in hydrodynamic diameter after 2 hours of incubation ( Figure 5E ). Consistent with cryo-388 EM and protease cleavage results, incubation of S with IMM20253 decreased the hydrodynamic 389 diameter of the resulting complexes, consistent with complex disruption. These data support a 390 unique mechanism of action for IMM20253 whereby binding disrupts the Trimeric architecture of 391 the S complex and facilitates cleavage into S1 and S2 in the presence of proteases. 392 393 394 DISCUSSION 395

We have described three unique antibodies with different mechanisms of action that bind to non-396 competing epitopes on S protein, trigger Trimer reorganization into one resembling a post-fusion 397 confirmation, and induce a potent antiviral response in vitro and in vivo. Further, we revealed a 398 unique mechanism of action of IMM20253; this antibody binds to a conserved epitope on Trimer 399

Spike and induces complex dissociation into monomers and cleavage into S1 and S2 subunits. IMM20190 was shown to be resistant to small changes in the RBD sequence. The epitope of 415 IMM20184 antibody is located in N370 -P384 region of the RBD and consists of 5 critical 416 residues, surrounding the RBD core (35), that is conserved in Omicron and all prior VOC of SARS-417

CoV-2 and other SARS-related coronaviruses (21, 22) . IMM20184 antibody has a higher affinity 418 to a soluble RBD, yet 5.7-fold slower dissociation from a soluble Trimer, indicating avid binding 419 to Trimer. The COVA-1 antibody that bound to the area adjacent to IMM20184 epitope has been 420 demonstrated to have strong cross-neutralizing properties due to its avid binding (21). The 421 remaining antibody IMM20253 does not directly compete with hACE2, but binds to a conserved 422 epitope (K356 and R466 residues) that is not a common target of the human immune system for 423 generating neutralizing antibodies (35). IMM20253 binding leads to a dissociation of Trimer into 424 S protein monomers, that likely facilitates cleavage into S1 and S2 in the presence of proteases. Hamsters were either treated one day before challenge, or 6 ± 1 hour after challenge via an 512 intraperitoneal (i.p.) injection. Animals were euthanized on Study Day 4. The lungs were 513 harvested and homogenized for viral titer determination via TCID50 or plaque assay. Viral 514 clearance levels obtained by the various treatments were compared to non-treated controls using 515 a two-way ANOVA with Tukey's multiple comparisons test. F-tests were performed using an 516 online calculator (https://www.statskingdom.com/220VarF2.html). 

In the context of pseudovirus neutralization, synergy between two or three monoclonal antibodies 551 in combination is defined as neutralization that is greater than neutralization by the most effective 552 monoclonal antibody alone. To test whether combinations of antibodies show synergy in 553 neutralizing SARS-CoV-2, we used an approach similar to one described previously (3). 554

Pseudovirus neutralization experiments were set up as described above, except that multiple 555 monoclonal antibodies were tested in combination. Briefly, for combinations of two antibodies, 556 one test article was titrated in the background of each concentration in a serial dilution of the other 557 test article. Single antibody titrations were included as controls. For combinations of three 558 antibodies, one test article was titrated in the background of each concentration in a serial dilution 559 of a 1:1 mixture of the other two test articles. To evaluate antibody synergy in the combinations, 560 the observed combination response matrix of pseudovirus neutralization was used as input for the 561 online SynergyFinder platform (4), where quadruplicate data points were input separately. The 562 highest single agent (HSA) reference model was applied, which quantifies synergy as the excess 563 over the maximum response of a single drug in the combination. Synergy between antibodies in 564 each combination is reported as an overall synergy score (the average of observed synergy across 565 the dose combination matrix) as well as a peak HSA score (the highest synergy score calculated 566 across the dose combination matrix). Synergy scores of less than -10, between -10 and 10, and 567 greater than 10 indicate antagonistic, additive, and synergistic antibody combinations, 568 respectively. While peak HSA scores report on synergy at the most optimal combination 569 concentrations, the overall synergy score is less affected by outlier data points. 570 571

Assay was performed with antibodies diluted to 100 ug/mL in PBS + 1% BSA. Antibodies were 573 subjected to overnight incubation on tube rotator at 4°C in the presence of bead-biotinylated 574 antigen mixture, followed by 3 washes. THP-1 cells were pelleted, resuspended in serum-free 575 RPM and then added to wells containing bead-antigen-antibody mixture. The bead-antigen-576 antibody-cells mixture was incubated with cells in CO2 incubator for 18 hours. After that, cells 577 were fixed and immunostained. Flow cytometry was peformed on Attune NXT and the resulted 578 data were analyzed using FlowJo Software. were selected from 1,055 manually curated micrographs using cryoSPARC 3.3 live. All 684 subsequent data processing was carried out in cryoSPARC 3.3. These particles were subjected to 685 one round of 2D classification. All micrographs from three sessions were combined for further 686 processing in cryoSPARC 3.3. ~1.9M particles were extracted and subjected to three rounds of 2D 687 classification analysis and about 600k particles were selected for ab initio reconstruction. The 688 particles were then subjected to three rounds of heterogenous refinement using the good and junk 689 classes from ab initio reconstruction as reference volume. The good particles were selected and 690 subjected to homogenous refinement and non-uniform refinement. The final 3D reconstruction 691 was at a nominal resolution of 3.87 Å using ~170K particles (see Sup. Figure 1E,F) 

Omicron escapes 699 the majority of existing SARS-CoV-2 neutralizing antibodies

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Effectiveness of Covid-19

Vaccines against the B.1.617.2 (Delta) Variant

A framework for research on vaccine effectiveness

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

A Little) Clarity on Convalescent Plasma for Covid-19

COVID-19 and Cancer Consortium, Association of Convalescent Plasma 736 Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Hunt for improved monoclonals against coronavirus gathers pace

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational 742 escape in preclinical and human studies In brief Treatment with monoclonal antibody 743 combinations limits generation of SARS-CoV-2 escape variants in humans and model anima

FDA Statement: Coronavirus (COVID-19) Update: FDA Limits Use of 746

Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant

FDA authorizes revisions to Evusheld dosing | FDA

Update: FDA Authorizes New Monoclonal Antibody for 754 Treatment of COVID-19 that Retains Activity Against Omicron Variant | FDA

Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. The Journal of Infectious 760 Diseases

CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of

Unbiased interrogation of memory B cells from convalescent COVID-19 773 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the 774 spike protein

Molecular determinants and mechanism for 778 antibody cocktail preventing SARS-CoV-2 escape

Cross-781 Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site

A 784 highly conserved cryptic epitope in the receptor binding domains of

Broad 790 and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Phylogenetic 793 Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary 794 Distinct and Proteolytically Sensitive Activation Loop

The dual function monoclonal antibodies VIR-7831 and VIR-7832 801 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv

SynergyFinder 2.0: Visual analytics of multi-drug 804 combination synergies

Human neutralizing antibodies 808 against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Antibody potency, effector function and combinations in protection 813 from SARS-CoV-2 infection in vivobioRxiv

Fc-engineered antibody therapeutics with improved efficacy against COVID-19

A robust, high-820 throughput assay to determine the phagocytic activity of clinical antibody samples

C1s Inhibition by BIVV009 823 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In 824 Vitro

Molecular 827 Basis of Assembly and Activation of Complement Component C1 in Complex with 828

Antigen Article Molecular Basis of Assembly and Activation of 829 Complement Component C1 in Complex with Immunoglobulin G1 and Antigen

834 Complement is activated by IgG hexamers assembled at the cell surface

Potent neutralizing 838 nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and 839 conserved epitopes

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that 842 affect recognition by polyclonal human plasma antibodies

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet 846 generates an able infection inhibitor

A potently neutralizing anti-SARS-CoV-2 849 antibody inhibits variants of concern by binding a highly conserved epitope

857 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

REGN-COV2 antibodies 864 prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

REGN-COV2, a Neutralizing Antibody Cocktail

Structure-based development of three-and four-antibody cocktails against SARS-874

CoV-2 via multiple mechanisms

ARTICLE OPEN Rational development of a human 880 antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small 885 intestinal enterocytes

A high-throughput shotgun mutagenesis approach to mapping B-887 cell antibody epitopes

TNT003, 889 an inhibitor of the serine protease C1s, prevents complement activation induced by cold 890 agglutinins

Automated molecular microscopy: The new Leginon system

MotionCor2: 895 Anisotropic correction of beam-induced motion for improved cryo-electron microscopyNature 896

CryoSPARC: Algorithms for rapid 898 unsupervised cryo-EM structure determination

CTFFIND4: Fast and accurate defocus estimation from electron 901 micrographs

Gctf: Real-time CTF determination and correction

Accelerated cryo-EM structure 906 determination with parallelisation using GPUS in RELION-2

H) SARS-CoV-2 isolates after pre-treatment (Day -1) 985 with different doses of 3-Ab cocktail IMM20190/184/253 at 1:1:1 ratio. Bar denotes median 986 values. Error bars denote interquartile range. Statistical analysis in panel B is Two-Way ANOVA 987 and in panels C-H is One-way ANOVA using Dunnet's multiple comparisons test comparing to 988 untreated group

Deposition of classical complement component C4 on IMM antibodies bound to Trimer

C) Activation of antibody-mediated cellular cytotoxicity (ADCC) by IMM antibodies and 1012 two antibody (IMM20184/20253) and three-antibody (IMM190/184/253) combinations bound to 1013

ELISA-based receptor competition assay. (B)

IMM20190 and IMM20253 antibodies to soluble RBD and Trimer (REF variant) measured using 1019

Surface Plasmon Resonance (SPR). (C) KD, Kon and Koff values of IMM20184

Western blot analysis of Trimer digested with protease K after 0, 15 and 60 min in the 1022 presence of either human ACE2, IMM20253 or IMM20190. Anti-S2 staining reveals S monomer 1023 (S1+S2) and S2 protein. (E) Dynamic light scattering (DLS) analysis of Trimer complex with 1024 either ACE2

Fab binding to Trimer triggers complex disruption and release of S monomers. (G) Schematic of 1026 mechanism of action of

Supplementary Table 1. Breadth of binding of IMM20190/184/253 antibodies to RBD 1039 proteins bearing mutations found in CDC VOCs. EC50 (pM) relative to respective reference 1040 proteins measured using hTRF assay

Supplementary Figure 1. Cryo-EM micrographs reveal sites of

Fabs binding to Spike protein. (A) Cryo-EM micrographs and 2D classification of Trimer-Fab 1054 complexes shown in Figure 1A. IMM20253 binding to Trimer generates two families

Comparison of 3D reconstruction data (density only) for a closed Trimer 1056 conformation, IMM20184 Fab-Trimer, IMM20190 Fab-Trimer and IMM20253 Fab-Trimer 1057 complexes in support of data shown in Figure 1A

Viewing directional distribution for the final 1064 refinement run for the complex shown in panels D and E, generated by cryoSPARC 3.3. The 1065 viewing direction distribution histogram shows the number of images with a particular viewing 1066 direction at each (elevation

Antibody binning on Octet Qke. IMM20184, IMM20190 and IMM20253 do not 1069 compete for soluble Trimer and RBD protein binding. Heat map values represent binding of the 1070 first antibody to Trimer (top), followed by binding of the second antibody (left)

Supplementary Figure 2. Antibody exposure and pharmacokinetics in dosed hamsters

Pharmacokinetics of the 3-Ab cocktail in hamsters. The 3-Ab cocktail (0.3 mg each) was 1076

Syrian Golden hamsters and terminal bleeds (n = 4 per time point) were 1077 taken at 0.25, 0.5. 1, 2, 4, 8, 24, 48, 96, and 168 hours post administration. Total human IgG levels 1078 were determined by anti-human ELISA

Green line is the calculated curve using the 1080 formula shown on the right. (B) PK parameters of data from panel A. (C) Viral titer in lungs of 1081 infected hamsters depends upon Ab exposure. Syrian golden hamsters challenged with 3.3x10 5 1082 TCID50 viral inoculation of a non-adapted WA_CDC-WA1/2020 SARS-CoV-2 isolate were 1083 treated with 3-Ab cocktail (IMM20184/IMM20190/IMM20253), at various dose levels, six hours 1084 post inoculation with virus. Lungs were harvested at day 4 post-treatment and viral titers were 1085 determined by TCID50 assay

Supplementary Figure 3. Three selected antibodies have a synergistic neutralizing effect

Neutralization properties of standalone IMM20190, IMM20184 and IMM20253 antibodies 1091 against 10 different Spike variant pseudoviruses. (B) REF, B.1.1.7 (alpha), B.1.351 (beta), P1 1092 (gamma), and B.1.427 (epsilon) pseudovirus variant neutralization by IMM20190 combination 1093 with either IMM20184, IMM20253 or both. (C) The Highest Single Agent (HSA) scores for

Ab and 3-Ab combinations. IMM20190 was mixed with IMM20184 and IMM20253 at 1:0.5:0.5 1095 ratio. (D) HSA scores for two and three antibody cocktail

Focus reduction neutralization assay (FRNT) of SARS-CoV-2 1099 variants in the presence of IMM20184, IMM20253 and IMM20253/184 combination